Shots:

• The US FDA’s approval is based on P-III ATTRACTION-3 study assessing Opdivo (240mg by IV infusion over 30min- q2w) vs taxane CT (docetaxel/paclitaxel) in patients with unresectable advanced- recurrent or ESCC- refractory/ intolerant to at least one prior fluoropyrimidine & platinum-based CT
• Opdivo is the first approved immunotherapy in this setting regardless of tumor PD-L1 expression level. Efficacy results: OS (10.9 vs 8.4mos.); ORR (19.3% vs 21.5%); median PFS (1.7 vs 3.4mos.)
• Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response

Click here to read full press release/ article |

Ref: Business wire | Image: BMS